Kidney cancer

Lancet

Volumn 352, Issue 9141, 1998, Pages 1691-1696

  Vogelzang, Nicholas J ^a   Stadler, Walter M ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; INTERLEUKIN 2;

AGE; CANCER RISK; CANCER SURVIVAL; CAVA VEIN; HEART ARREST; HEART RIGHT ATRIUM; HUMAN; INDUCED HYPOTHERMIA; KIDNEY CANCER; METASTASIS; NEPHRECTOMY; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; REVIEW; SEX RATIO; THORACOTOMY; TUMOR SUPPRESSOR GENE; TUMOR THROMBUS; UNITED STATES;

EID: 0032556354     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)01041-1     Document Type: Review

References (79)

1. 1 Ries LAG, Kosary CL, Hankey BF, Miller BA, Harras A, Edwards BK, eds. SEER cancer statistics review, 1973-1994, National Cancer Institute. Bethesda: NIH Publication 97-2789, 1997.
2. 2 Marshall FF, Stewart AK, Menck HR. The National Cancer Data Base: report on kidney cancers. Cancer 1997; 80: 2167-74.
3. 3 Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med 1996; 355: 865-75.
4. 4 McLaughlin JK, Blot WJ, Devesa SS, Fraumeni JF Jr. Renal cancer. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer epidemiology and prevention, 2nd edn. Oxford: Oxford University Press, 1996: 1142-53.
5. 5 Herring JC, Schmetz MA, Digan AB, Young ST, Kalloo NB. Renal medullary carcinoma: a recently described highly aggressive renal tumor in young black patients. J Urol 1997; 157: 2246-47.
6. 6 Nishikubo CY, Kunkel LA, Figlin R, et al. An association between renal cell carcinoma and lymphoid malignancies: a case series of eight patients. Cancer 1996; 78: 2421-26.
7. 7 Choyke PL, Glenn G, Walther MM, et al. The natural history of renal lesions in von Hippel-Lindau syndrome: a serial study in 28 patients. Am J Roentgenol 1992; 159: 1229-34.
8. ++ transporting ATPase isoform 2 gene that resides in the Von Hippel-Lindau gene region. Science 1993; 53: 861-67.
9. 9 Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7: 85-90.
10. 10 Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr. Tumor suppression by the human von Hippel-Lindau gene product. Nat Med 1995; 1: 822-26.
11. 11 Lonergan K, Iliopoulos O, Ohh M, et al. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 1998; 18: 732-41.
12. 12 Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-47.
13. 13 Gronwald J, Storkel S, Holtgreve-Grez H, et al. Comparison of DNA gains and losses in primary renal clear cell carcinomas and metastatic sites: importance of 1q and 3p copy number changes in metastatic events. Cancer Res 1997; 57: 481-87.
14. 14 Theillet C. Full speed ahead for tumor screening. Nat Med 1998; 4: 767-68.
15. 15 Bosniak MA, Krinsky GA, Waisman J. Management of small incidental renal parenchymal tumors by watchful waiting in selected patients based on observations of growth rate. J Urol 1996; 155: 584-91.
16. 16 Aso Y, Homma Y. A survey of incidental renal cell carcinoma in Japan. J Urol 1992; 147: 340-43.
17. 17 Ishikawa I, Kovacs G. High incidence of papillary renal cell tumours in patients on chronic haemodialysis. Histopathology 1993; 22: 135-39.
18. 18 Coughlin SS, Neaton JD, Randall B, Sengupta A. Predictors of mortality from kidney cancer in 332 547 men screened for the multiple risk intervention trial. Cancer 1997; 79: 2171-77.
19. 19 van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al. Second cancer risk following testicular cancer: a follow-up study of 1909 patients. J Clin Oncol 1993; 11: 415-24.
20. 20 Vogelzang NJ, Yang X, Goldman S, Vijayakumar S, Steinberg G. Radiation-induced renal cell cancer: a report of four cases and review of the literature. J Urol (in press).
21. 21 Gelb AB, Shibuya RB, Weiss LM, Medeiros LJ. Stage I renal cell carcinoma: a clinicopathologic study of 82 cases. Am J Surg Pathol 1993; 17: 275-86.
22. 22 Guinan PD, Vogelzang NJ, Fremgen AM, et al. Renal cell carcinoma: tumor size, stage and survival. J Urol 1995; 153: 901-03.
23. 23 Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma, workgroup no 1. Cancer 1997; 80: 987-89.
24. 24 Uhlman DL, Ngugen PL, Manivel JC, et al. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 1994; 86: 1470-75.
25. 25 Oda H, Nakatsuru Y, Ishikawa T. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res 1995; 55: 354-59.
26. 26 Figlin RA, Pierce WC, Kaboo R, et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 1997; 158: 740-45.
27. 27 Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57: 1537-46.
28. 28 Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969; 101: 297-301.
29. 29 Novick AC, Strem SB. Surgery of the kidney. In: Walsh PC, Patik AB, Vaughan ED, Wein AJ, eds. Campbell's Urology, 7th edn. Philadelphia: W B Saunders, 1998: 2973-3061.
30. 30 Levy DA, Slaton JW, Swanson A, Dinney CPN. Guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998; 159: 1163-67.
31. 31 Studer UE, Scherz S, Scheidegger J, et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 1990; 144: 243-45.
32. 32 Bukowski RM, Novick AC. Clinical practice guidelines: renal cell carcinoma. Cleve Clin J Med 1997; 64: 4-44.
33. 33 Blom JHM. The role of lymphadenectomy in association with radical nephrectomy. Curr Opin Urol 1993; 3: 359-62.
34. 34 Nelson JF, Marshall FF. Surgical treatment of locally advanced renal cell carcinoma. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, eds. Comprehensive textbook of genitourinary oncology. Baltimore: Williams & Wilkins, 1996: 218-36.
35. 35 McCaffrey JA, Motzer RJ. What is the role of nephrectomy in patients with metastatic renal cell carcinoma? Semin Oncol 1996; 23: xix-xx.
36. 36 Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998; 16: 2261-66.
37. 37 Walther MM, Yang JC, Pass HI, Linehan WM, Rosenberg SA. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 1997; 158: 1675-78.
38. 38 Galligioni E, Quaia M, Merlo A, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 1996; 77: 2560-66.
39. 39 Trump DL, Elson P, Propert K, et al. Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon in resected, high-risk renal cell carcinoma. Proc Am Soc Clin Oncol 1996; 15: 648 (abstr).
40. 40 Pizzocaro G, Piva L, Costa A, Silvestrini R. Adjuvant interferon to radical nephrectomy in Robson's stages II and III renal cell cancer, a multicenter randomized tudy with some biological evaluations. Proc Am Soc Clin Oncol 1997; 16: 1132 (abstr).
41. 0 renal cell carcinoma. Proc Am Soc Clin Oncol 1997; 16: 326a (abstr).
42. 42 Green DM, Breslow NE, Beckwith JB, Moksness J, Finklestein JZ, D'Angio GJP. Treatment of children with clear-cell sarcoma of the kidney: a report from the national Wilm's tumor study group. J Clin Oncol 1994; 112: 2132-37.
43. 43 Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995; 22: 42-60.
44. 44 Tobe SW, Noble-Topham SE, Andrulis IL, Hartwick WJ, Skorecki KL, Warner E. Expression of the multiple drug resistance gene in human renal cell carcinoma depends on tumor histology, grade, and stage. Clin Cancer Res 1995; 1: 1611-15.
45. 45 Mertens WC, Eisenhauer EA, Moore M, et al. Gemcitabine in advanced renal cell carcinoma: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1993; 4: 331-32.
46. 46 DeMulder PH, Weissbach L, Jakse G, Osieka R, Blatter J. Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 1996; 37: 491-95.
47. 47 Mani S, Gordon G, Vogelzang NJ, et al. A phase I trial of continuous 5-fluorouracil and weekly gemcitabine: updated results of an active combination for renal cell, hepatocellular and colon carcinoma. Ann Oncol 1998; 9 (suppl 2): 165 (abstr 632).
48. 48 Motzer RJ, Vogelzang NJ. Chemotherapy for renal cell carcinoma. In: Raghavan D, Scher HI, Leibel SA, Lange PH, eds. Principles and practice of genitourinary oncology. Philadelphia: Lippincott-Raven, 1997: 885-96.
49. 49 Quesada JR, Swanson DA, Trindade A, Gutterman JU. Renal cell carcinoma: anti-tumor effects of leukocyte interferon. Cancer Res 1983; 43: 940-47.
50. 50 Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993; 11: 1368-75.
51. 51 Steineck G, Strander H, Carbin BE, et al. Recombinant leucocyte interferon alpha-2A and medroxyprogesterone in advanced renal cell carcinoma. Acta Oncol 1990; 29: 155-62.
52. 52 Kriegmair M, Oberneder R, Hofstetter A. Interferon alpha and vinblastine versus medroxyprogersterone acetate in the treatment of metastatic renal cell carcinoma. Urology 1995; 45: 758-62.
53. 53 Pyrhonan S, Salminen E, Lehtonen T, et al. Recombinant interferon alfa 2a with vinblastine vs vinblastine alone in advanced renal cell carcinoma. Proc Am Soc Clin Oncol 1996; 15: 614 (abstr).
54. 54 Ritchie AWS, Griffiths G, Cook P, Oliver RTD, Hancock B, Parmar MKB. Alpha interferon improves survival in patients with metastatic renal carcinoma - preliminary results of an MRC randomized controlled trial. Proc Am Soc Clin Oncol 1998; 17: 1194.
55. 55 Gleave ME, Elhilali M, Fradet Y, et al, and the Canadian Urologic Oncology Group. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1265-71.
56. 56 Rosenberg SA, Lotze MT, Muul J, et al. Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485-92.
57. 57 Fisher RI, Colman CA Jr, Doroshow JH, et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells: a phase II clinical trial. Ann Intern Med 1988; 108: 518-23.
58. 58 Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose interleukin-2 therapy. J Clin Oncol 1995; 13: 688-96.
59. 59 Atkins M, Sparano J, Fisher R, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993; 11: 661-70.
60. 60 Margolin K, Atkins M, Sparano J, et al. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin-2 therapy in advanced renal cancer and malignant melanoma. Clin Cancer Res 1997; 3: 565-72.
61. 61 Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991; 9: 694-704.
62. 62 Yang YC, Topalian SL, Parkinson D, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994; 12: 1572-76.
63. 63 Goey SH, Verweij J, Stoter G. Immunotherapy of metastatic renal cell cancer. Ann Oncol 1996; 7: 887-900.
64. 64 Tzannis ST, Hrushesky WJM, Wood PA, Przybycien TM. Irreversible inactivation of interleukin 2 in a pump-based delivery environment. Proc Natl Acad Sci USA 1996; 93: 5460-65.
65. 65 Stadler WM, Kuzel T, Dumas M, Vogelzang NJ. A multi-center phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal cell carcinoma. J Clin Oncol 1998; 16: 1820-25.
66. 66 Vogelzang NJ, Lipton A, Figlin R. Subcutaneous interleukin-2 plus interferon alpha-2A in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 1993; 11: 1809-16.
67. 67 Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high dose interleukin-2 alone or in conjunction with lymphokine activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85: 622-32.
68. 68 Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma. Cancer 1997; 80: 1198-220.
69. 69 Osband ME, Lavin PT, Babayan RK, et al. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 1990; 335: 994-98.
70. 70 Hanninen EL, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 1996; 155: 19-25.
71. 71 Tourani J-M, Pfister C, Berdah J-F, et al. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. J Clin Oncol 1998; 16: 2205-13.
72. +, recombinant human interferon alfa 2a, or both in metastatic renal cell carcinoma. N Engl J Med 1998; 338: 1272-78.
73. 73 Atzpodien J, Kirchner H, Franzke A, et al. Results of a randomized clinical trial comparing SC interleukin-2, SC alpha-2a-interferon, and IV bolus 5-fluororacil against oral tamoxifen in progressive metastatic renal cell carcinoma patients. Proc Am Soc Clin Oncol 1997; 16: 326 (abstr).
74. 74 Henriksson R, Nilsson S, Colleen S, et al. Survival in renal cell carcinoma - a randomised evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen. Br J Cancer 1998; 77: 1311-17.
75. 75 Kranenborg MHGC, Boerman OC, de Weijert MCA, Oosterwijk-Wakka JC, Corstens FHM, Oosterwijk E. The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts. Cancer 1997; 80: 2390s-97s.
76. 76 Carlson DL, Williams JW, Rollins-Smith LA, et al. Pronephric carcinoma: chromosomes of cells rescued from apoptosis by an oncogenic herpesvirus detected with a polymerase chain reaction. J Comp Pathol 1995; 113: 277-86.
77. 77 Wiggington JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrout RH. Administration of interleukin-12 with pulse interleukin-2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 1996; 88: 38-43.
78. 78 Stadler WM, Shapiro CL, Sosman J, Clark J, Vogelzang NJ, Kuzel T. A multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal cell carcinoma (RCC). Proc ASCO 1998; 17: 1192 (abstr).
79. 79 Schipper H, Turley EA, Baum M. A new biological framework for cancer research. Lancet 1996; 348: 1149-51.